Institute of Anatomy and Cell Biology
Sandra Meyer has not added Biography.
If you are Sandra Meyer and would like to personalize this page please email our Author Liaison for assistance.
The German network of excellence for viral hepatitis (Hep-Net).
Hepatology (Baltimore, Md.) Sep, 2003 | Pubmed ID: 12939578
Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans.
Journal of immunology (Baltimore, Md. : 1950) Nov, 2003 | Pubmed ID: 14568963
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
Journal of medicinal chemistry Mar, 2005 | Pubmed ID: 15771427
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Journal of medicinal chemistry Mar, 2005 | Pubmed ID: 15771440
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
AIDS (London, England) Jun, 2005 | Pubmed ID: 15905675
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
Antimicrobial agents and chemotherapy Jun, 2005 | Pubmed ID: 15917527
DC-SIGN mediates binding of dendritic cells to authentic pseudo-LewisY glycolipids of Schistosoma mansoni cercariae, the first parasite-specific ligand of DC-SIGN.
The Journal of biological chemistry Nov, 2005 | Pubmed ID: 16155001
Discovery of complex mixtures of novel long-chain quorum sensing signals in free-living and host-associated marine alphaproteobacteria.
Chembiochem : a European journal of chemical biology Dec, 2005 | Pubmed ID: 16283687
One-step biotinylation procedure for carbohydrates to study carbohydrate-protein interactions.
Analytical biochemistry Jul, 2006 | Pubmed ID: 16713984
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
Journal of acquired immune deficiency syndromes (1999) Sep, 2007 | Pubmed ID: 17621237
The C-type lectin L-SIGN differentially recognizes glycan antigens on egg glycosphingolipids and soluble egg glycoproteins from Schistosoma mansoni.
Glycobiology Oct, 2007 | Pubmed ID: 17621595
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
AIDS (London, England) Jan, 2008 | Pubmed ID: 18090413
Resistance profile of darunavir: combined 24-week results from the POWER trials.
AIDS research and human retroviruses Mar, 2008 | Pubmed ID: 18327986
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
AIDS (London, England) Jul, 2008 | Pubmed ID: 18614861
Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.
Journal of acquired immune deficiency syndromes (1999) Oct, 2008 | Pubmed ID: 18769351
Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.
Journal of acquired immune deficiency syndromes (1999) Dec, 2008 | Pubmed ID: 19202459
Transglycosylation-based fluorescent labeling of 6-gala series glycolipids by endogalactosylceramidase.
Glycobiology Jul, 2009 | Pubmed ID: 19389917
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
AIDS (London, England) Sep, 2009 | Pubmed ID: 19474650
Multipotent adult germline stem cells and embryonic stem cells: comparative proteomic approach.
Journal of proteome research Dec, 2009 | Pubmed ID: 19810753
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
Antiviral therapy , 2009 | Pubmed ID: 19812449
Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V Feb, 2010 | Pubmed ID: 19861163
Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts.
International journal of radiation biology Nov, 2009 | Pubmed ID: 19895274
Glycolytic metabolism and tumour response to fractionated irradiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Jan, 2010 | Pubmed ID: 20036432
[Diagnosis of delirium].
Therapeutische Umschau. Revue thérapeutique Feb, 2010 | Pubmed ID: 20131214
[Drug-induced delirium].
Therapeutische Umschau. Revue thérapeutique Feb, 2010 | Pubmed ID: 20131216
Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.
AIDS (London, England) Mar, 2010 | Pubmed ID: 20160633
Schistosoma mansoni worm glycolipids induce an inflammatory phenotype in human dendritic cells by cooperation of TLR4 and DC-SIGN.
Molecular immunology Apr, 2010 | Pubmed ID: 20170964
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
AIDS research and human retroviruses Jun, 2010 | Pubmed ID: 20507207
Digital gene expression signatures for maize development.
Plant physiology Nov, 2010 | Pubmed ID: 20833728
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Antiviral therapy , 2010 | Pubmed ID: 21149923
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Antiviral therapy , 2011 | Pubmed ID: 21311113
Multipotent adult germline stem cells and embryonic stem cells functional proteomics revealed an important role of eukaryotic initiation factor 5A (Eif5a) in stem cell differentiation.
Journal of proteome research Apr, 2011 | Pubmed ID: 21344951
Telaprevir for retreatment of HCV infection.
The New England journal of medicine Jun, 2011 | Pubmed ID: 21696308
Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
Current HIV research Mar, 2012 | Pubmed ID: 22339125
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
PloS one , 2012 | Pubmed ID: 22511937
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
Hepatology (Baltimore, Md.) Dec, 2012 | Pubmed ID: 22806681
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
Journal of virology Feb, 2013 | Pubmed ID: 23152524
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.
Journal of hepatology Mar, 2013 | Pubmed ID: 23183521
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.
Journal of hepatology May, 2013 | Pubmed ID: 23321318
Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
Antiviral therapy , 2013 | Pubmed ID: 23558157
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Jul, 2013 | Pubmed ID: 23575197
Duplicated STM-like KNOX I genes act in floral meristem activity in Eschscholzia californica (Papaveraceae).
Development genes and evolution May, 2013 | Pubmed ID: 23636178
Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
The Journal of infectious diseases Sep, 2013 | Pubmed ID: 23801602
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Gastroenterology Mar, 2014 | Pubmed ID: 24316262
Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology Mar, 2014 | Pubmed ID: 24462470
Synthesis and pharmacological evaluation of a new series of radiolabeled ligands for 5-HT7 receptor PET neuroimaging.
Nuclear medicine and biology Apr, 2014 | Pubmed ID: 24607435
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.
Virology journal , 2014 | Pubmed ID: 24886541
Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.
The Journal of infectious diseases Dec, 2014 | Pubmed ID: 24943725
Modeling viral evolutionary dynamics after telaprevir-based treatment.
PLoS computational biology Aug, 2014 | Pubmed ID: 25101970
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
Liver international : official journal of the International Association for the Study of the Liver Feb, 2015 | Pubmed ID: 25319731
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
Journal of hepatology May, 2015 | Pubmed ID: 25445400
Effect of Agrobacterium strain and plasmid copy number on transformation frequency, event quality and usable event quality in an elite maize cultivar.
Plant cell reports May, 2015 | Pubmed ID: 25558819
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.
Antiviral research Apr, 2015 | Pubmed ID: 25614456
DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY.
Psychoneuroendocrinology Mar, 2015 | Pubmed ID: 25635612
An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
Journal of clinical microbiology Apr, 2015 | Pubmed ID: 25653396
Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.
AIDS research and human retroviruses Jun, 2015 | Pubmed ID: 25684627
Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
Antimicrobial agents and chemotherapy May, 2015 | Pubmed ID: 25712364
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유